Medindia

X

SuperGen to Present at UBS Global Life Sciences Conference on September 25, 2008

Thursday, September 18, 2008 General News J E 4
Advertisement
DUBLIN, Calif., Sept. 18 SuperGen, Inc.(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapiddevelopment and commercialization of therapies for solid tumors andhematological malignancies, today announced that James S. Manuso, Ph.D.,President and Chief Executive Officer, is scheduled to present at the UBSGlobal Life Sciences Conference on Thursday, September 25, 2008, at The GrandHyatt New York.

SuperGen's presentation at the UBS Global Life Sciences Conference isscheduled to begin at 12:30 p.m. EDT (9:30 a.m. PDT). A live webcast of thepresentation will be available on the investor relations section of theCompany's Web site at http://www.supergen.com. A webcast replay of thepresentation will be available shortly following the live event.

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical companydedicated to the discovery and development of novel cancer therapies. SuperGenis developing a number of therapeutic anticancer products focused on kinaseand cell signaling inhibitors and DNA methyltransferase inhibitors. For moreinformation about SuperGen, please visit http://www.supergen.com.Contacts: SuperGen, Inc. Dorland Global Public Relations Timothy L. Enns Michael Beckerich (Media) SVP, Corporate Communications Tel: (212) 677-7632 & Business Development mbeckerich@dorland.com Tel: (925) 560-0100 Email: tenns@supergen.com Mary M. Vegh Manager, Investor Relations Tel: (925) 560-2845 E-mail: mary.vegh@supergen.com

SOURCE SuperGen, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Agendia's MammaPrint(R) Included in 2008 Dutch Ins...
S
Dermatologists Continue to Use Enbrel Over Humira ...